Krka, d. d., Novo mesto stock (SI0031102120): dividend and 2025 outlook in focus

Krka, d. d., Novo mesto remains in the spotlight after publishing 2024 results and a proposed dividend for 2025, drawing interest from income-focused investors who follow European pharmaceuticals from the US.

Krka, d. d., Novo mesto, a Slovenian pharmaceutical group, has attracted fresh investor attention after reporting its 2024 financial results and outlining a proposed dividend for the 2025 financial year, according to the company’s annual report and related disclosures published in March 2025 on its website Krka website as of 03/28/2025. For US-based investors tracking European healthcare names, the combination of steady earnings, a cash dividend proposal and international exposure keeps the stock on the radar, as summarized in the firm’s investor materials released in early 2025 Krka investor relations as of 04/02/2025.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Krka
• Sector/industry: Pharmaceuticals and generics
• Headquarters/country: Novo mesto, Slovenia
• Core markets: Central and Eastern Europe, Western Europe, overseas markets
• Key revenue drivers: Prescription drugs, non-prescription products, animal health, health resort services
• Home exchange/listing venue: Ljubljana Stock Exchange (ticker KRKG)
• Trading currency: Euro (EUR)

Krka, d. d., Novo mesto: core business model

Krka, d. d., Novo mesto operates as a branded generics and pharmaceutical producer with a focus on prescription medicines, over-the-counter products and animal health solutions. The company’s strategy emphasizes vertically integrated development and production, covering the pathway from active pharmaceutical ingredient manufacturing to finished dosage forms sold under its own brands in multiple international markets, according to corporate profile information presented in its investor relations materials published in 2024 Krka at a glance as of 09/18/2024.

The group has historically concentrated on therapeutic areas such as cardiovascular diseases, central nervous system disorders and gastrointestinal conditions, complemented by a portfolio of anti-infectives and treatments for metabolic diseases. Management describes a business model that blends in-house research and development with a broad network of manufacturing and packaging facilities located in Slovenia and abroad, seeking to ensure supply security and cost efficiency, as outlined in its annual report for 2023 released in April 2024 Krka annual report 2023 as of 04/13/2024.

Distribution is organized through subsidiaries and representative offices spanning Central and Eastern Europe, Western Europe and certain overseas regions. In its published strategy documents, Krka emphasizes maintaining a diversified geographic footprint to reduce dependence on any single country, while still prioritizing markets with favorable demographic trends and established healthcare reimbursement systems. This approach aims to support resilient earnings even when individual markets face pricing pressure or regulatory changes, according to the same 2023 annual report released in April 2024 Krka annual report 2023 as of 04/13/2024.

Main revenue and product drivers for Krka, d. d., Novo mesto

Krka’s largest revenue contribution typically comes from prescription pharmaceuticals, especially branded generics in cardiovascular and central nervous system indications. In its 2024 results presentation, the company reported that prescription drugs remained the dominant segment within total sales, reflecting ongoing demand in core markets in Europe and selected international regions, according to figures disclosed in March 2025 Krka presentations as of 03/28/2025. New product launches, line extensions and formulation improvements are highlighted as levers to defend market share against other generics producers and originator companies.

Non-prescription, over-the-counter products form a second important pillar. These include vitamins, minerals and various self-medication products that are often marketed directly to consumers through pharmacies. While smaller in scale than prescription drugs, this business offers higher brand recognition and the potential for margin support in certain categories, according to the company’s description of its product mix in the 2023 annual report published in April 2024 Krka annual report 2023 as of 04/13/2024. The firm also operates in animal health, supplying veterinary medicines for pets and livestock, which further diversifies revenues.

Geographically, Krka’s sales are spread across Central and Eastern Europe, Western Europe and overseas markets, including parts of Asia and Latin America. Management has previously pointed out that diversification across more than 70 countries helps balance currency swings and local regulatory shifts, as mentioned in an investor presentation from 2024 published on the company’s website Krka presentations as of 10/05/2024. For US investors, this global spread offers indirect exposure to emerging healthcare demand in Central and Eastern Europe and beyond, without concentrating on the US reimbursement and pricing environment.

Conclusion

Krka, d. d., Novo mesto positions itself as a diversified European pharmaceutical group with a focus on branded generics, non-prescription products and animal health, supported by vertically integrated production and a broad geographic footprint. Recent disclosures on 2024 financials and the proposed 2025 dividend underline the company’s focus on cash returns alongside continued investment in research, development and manufacturing capacity, as indicated in materials published in March 2025 Krka investor relations as of 03/28/2025. For US-based investors following international healthcare names, the stock offers exposure to Central and Eastern European pharmaceutical demand and euro-denominated cash flows, while also carrying the usual sector-specific risks linked to regulation, patent challenges and pricing dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.